A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup ATRTs.

Brian GolbournBen HoAndrew BondocAmanda LuckXiaolian FanElizabeth RichardsonRichard MarcellusMichael PrakeschMathew HalbertNishant AgrawalChristian SmithAnnie HuangJames T Rutka

Published in: Neuro-oncology (2024)

Taken together our studies suggest combined treatments with PDGFR and ERBB2-directed TKIs with inhibitors of the PI3K and MAPK pathways as an important new therapeutic strategy for the MYC/TYR subgroup of ATRTs.

Keyphrases

tyrosine kinase
transcription factor
signaling pathway
climate change
phase iii
genome wide
high throughput
epidermal growth factor receptor
randomized controlled trial
clinical trial
case control
cell proliferation
dna methylation
drug induced
open label
chronic myeloid leukemia